Zentalis Pharmaceuticals (ZNTL)
(Delayed Data from NSDQ)
$1.41 USD
+0.02 (1.44%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $1.42 +0.01 (0.71%) 4:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ZNTL 1.41 +0.02(1.44%)
Will ZNTL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ZNTL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ZNTL
Zentalis Pharmaceuticals (ZNTL) Loses -46.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zentalis Pharmaceuticals (ZNTL) Upgraded to Strong Buy: What Does It Mean for the Stock?
ZNTL: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Buy Stocks for January 9th
Biotech Stock Roundup: GILD, NUVL Stocks Surge on Study Data, MRNA Down on Updates
Zentalis Stock Up as FDA Lifts Partial Hold on Cancer Drug Studies
Other News for ZNTL
Zentalis management to meet with Oppenheimer
ZNTL Hosts Investor Meetings in Mid-July | ZNTL Stock News
Zentalis management to meet with Oppenheimer
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | ZNTL ...
Zentalis Pharmaceuticals Holds 2025 Annual Stockholders Meeting